Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Leronlimab is an anti-inflammatory medication; its primary competitor for Covid 19 is Dexamethasone.

If Brilacidin proves to be an effective antiviral for Covid 19 its primary competitor will be Remdesivir.

Even if Leronolib becomes the primary Covid19 anti-inflammatory drug it does not, "raise the bar" for Brilacidin one millimeter.

Dexamethasone has become widely used for Covid19. It has a long history as an inexpensive synthetic corticosteroid with multiple indications.

Dexamethasone was shown to significantly reduce mortality against Covid19 in an extremely well done 11,000 patient British study published in the NEJM.

https://www.nejm.org/doi/full/10.1056/NEJMoa2021436

"Dexamethasone reduced deaths by one-third in ventilated patients and by one fifth in other patients receiving oxygen only.There was no benefit among those patients who did not require respiratory support."

https://www.gmmh.nhs.uk/download.cfm?doc=docm93jijm4n7645.pdf&ver=10221

It is Leronlimab, even with its potentially promising study, which still has a significant bar to overcome.

GLTA, Farrell